13-32355341-C-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000059.4(BRCA2):​c.7435+53C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0416 in 1,587,692 control chromosomes in the GnomAD database, including 2,142 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).

Frequency

Genomes: 𝑓 0.041 ( 220 hom., cov: 31)
Exomes 𝑓: 0.042 ( 1922 hom. )

Consequence

BRCA2
NM_000059.4 intron

Scores

2

Clinical Significance

Benign reviewed by expert panel B:12O:1

Conservation

PhyloP100: -0.300

Publications

17 publications found
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]
BRCA2 Gene-Disease associations (from GenCC):
  • breast-ovarian cancer, familial, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), ClinGen
  • Fanconi anemia complementation group D1
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen, G2P
  • pancreatic cancer, susceptibility to, 2
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • sarcoma
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • hereditary breast ovarian cancer syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • medulloblastoma
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.91).
BP6
Variant 13-32355341-C-T is Benign according to our data. Variant chr13-32355341-C-T is described in ClinVar as Benign. ClinVar VariationId is 126136.Status of the report is reviewed_by_expert_panel, 3 stars.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.107 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BRCA2NM_000059.4 linkc.7435+53C>T intron_variant Intron 14 of 26 ENST00000380152.8 NP_000050.3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BRCA2ENST00000380152.8 linkc.7435+53C>T intron_variant Intron 14 of 26 5 NM_000059.4 ENSP00000369497.3
BRCA2ENST00000530893.7 linkc.7066+53C>T intron_variant Intron 14 of 26 1 ENSP00000499438.2
BRCA2ENST00000614259.2 linkn.7435+53C>T intron_variant Intron 13 of 25 2 ENSP00000506251.1

Frequencies

GnomAD3 genomes
AF:
0.0405
AC:
6164
AN:
152018
Hom.:
217
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0206
Gnomad AMI
AF:
0.0264
Gnomad AMR
AF:
0.0974
Gnomad ASJ
AF:
0.0430
Gnomad EAS
AF:
0.101
Gnomad SAS
AF:
0.115
Gnomad FIN
AF:
0.0146
Gnomad MID
AF:
0.0380
Gnomad NFE
AF:
0.0340
Gnomad OTH
AF:
0.0474
GnomAD4 exome
AF:
0.0417
AC:
59897
AN:
1435556
Hom.:
1922
Cov.:
31
AF XY:
0.0444
AC XY:
31734
AN XY:
714762
show subpopulations
African (AFR)
AF:
0.0197
AC:
646
AN:
32790
American (AMR)
AF:
0.0752
AC:
3310
AN:
44036
Ashkenazi Jewish (ASJ)
AF:
0.0401
AC:
1039
AN:
25886
East Asian (EAS)
AF:
0.122
AC:
4756
AN:
39080
South Asian (SAS)
AF:
0.114
AC:
9614
AN:
84048
European-Finnish (FIN)
AF:
0.0149
AC:
787
AN:
52902
Middle Eastern (MID)
AF:
0.0560
AC:
310
AN:
5532
European-Non Finnish (NFE)
AF:
0.0337
AC:
36747
AN:
1091870
Other (OTH)
AF:
0.0452
AC:
2688
AN:
59412
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
2665
5330
7995
10660
13325
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
1480
2960
4440
5920
7400
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0406
AC:
6183
AN:
152136
Hom.:
220
Cov.:
31
AF XY:
0.0433
AC XY:
3223
AN XY:
74396
show subpopulations
African (AFR)
AF:
0.0206
AC:
856
AN:
41506
American (AMR)
AF:
0.0981
AC:
1498
AN:
15274
Ashkenazi Jewish (ASJ)
AF:
0.0430
AC:
149
AN:
3468
East Asian (EAS)
AF:
0.101
AC:
521
AN:
5176
South Asian (SAS)
AF:
0.115
AC:
553
AN:
4822
European-Finnish (FIN)
AF:
0.0146
AC:
154
AN:
10578
Middle Eastern (MID)
AF:
0.0340
AC:
10
AN:
294
European-Non Finnish (NFE)
AF:
0.0340
AC:
2314
AN:
67996
Other (OTH)
AF:
0.0492
AC:
104
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
303
606
908
1211
1514
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
74
148
222
296
370
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0343
Hom.:
34
Bravo
AF:
0.0419
Asia WGS
AF:
0.109
AC:
378
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:12Other:1
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not specified Benign:4
-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Nov 01, 2017
GeneKor MSA
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Breast-ovarian cancer, familial, susceptibility to, 2 Benign:3Other:1
Jan 12, 2015
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.1031 (Asian), 0.01423 (African), 0.03694 (European), derived from 1000 genomes (2012-04-30). -

-
GreenArray Genomic Research & Solutions of Accurate Diagnostic Private Limited
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breast Cancer Information Core (BIC) (BRCA2)
Significance:not provided
Review Status:no classification provided
Collection Method:clinical testing

- -

Oct 09, 2014
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Nov 03, 2021
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Hereditary cancer-predisposing syndrome Benign:2
Nov 19, 2014
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Dec 09, 2014
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary breast ovarian cancer syndrome Benign:1
Apr 19, 2022
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.91
CADD
Benign
3.5
DANN
Benign
0.54
PhyloP100
-0.30
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs11147489; hg19: chr13-32929478; COSMIC: COSV107498155; API